Cameco (XSWX:CCO) ROCE %

: 6.73% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cameco's annualized ROCE % for the quarter that ended in Dec. 2023 was 6.73%.

Cameco ROCE % Historical Data

The historical data trend for Cameco's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cameco Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

3.08

0.24

-0.61

1.98

6.68

Cameco Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-0.05	8.54	2.82	10.67	6.73

Cameco ROCE % Calculation

Cameco's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	373.353	/	( ( (5919.993 - 384.6)	+	(6403.527 - 766.501) )	/ 2 )
	=	373.353	/	( (5535.393	+	5637.026)	/ 2 )
	=	373.353	/	5586.2095
	=	6.68 %

Cameco's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	363.368	/	( ( (5797.577 - 635.837)	+	(6403.527 - 766.501) )	/ 2 )
	=	363.368	/	( ( 5161.74	+	5637.026 )	/ 2 )
	=	363.368	/	5399.383
	=	6.73 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cameco (XSWX:CCO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cameco ROCE % Related Terms

Thank you for viewing the detailed overview of Cameco's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cameco (XSWX:CCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Energy » Other Energy Sources » Cameco Corp (XSWX:CCO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CCJ:USA CJ6:Germany CCO:Canada

Address

2121 - 11th Street West, Saskatoon, SK, CAN, S7M 1J3

Website

https://www.cameco.com

Cameco Corp is one of the world's largest uranium producers. When operating at normal production, the flagship McArthur River mine in Saskatchewan accounts for roughly 50% of output in normal market conditions. Amid years of uranium price weakness, the company has reduced production, instead purchasing from the spot market to meet contracted deliveries. In the long term, Cameco has the ability increase annual uranium production by restarting shut mines and investing in new ones. In addition to its large uranium mining business, Cameco operates uranium conversion and fabrication facilities.